257 related articles for article (PubMed ID: 17853922)
41. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
Fu X; Meng F; Tao L; Jin A; Zhang X
Gene Ther; 2003 Aug; 10(17):1458-64. PubMed ID: 12900760
[TBL] [Abstract][Full Text] [Related]
42. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.
Mace AT; Ganly I; Soutar DS; Brown SM
Head Neck; 2008 Aug; 30(8):1045-51. PubMed ID: 18615711
[TBL] [Abstract][Full Text] [Related]
43. Regulation of herpes simplex virus 1 replication using tumor-associated promoters.
Mullen JT; Kasuya H; Yoon SS; Carroll NM; Pawlik TM; Chandrasekhar S; Nakamura H; Donahue JM; Tanabe KK
Ann Surg; 2002 Oct; 236(4):502-12; discussion 512-3. PubMed ID: 12368679
[TBL] [Abstract][Full Text] [Related]
44. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
45. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.
Veerapong J; Bickenbach KA; Shao MY; Smith KD; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2007 Sep; 67(17):8301-6. PubMed ID: 17804745
[TBL] [Abstract][Full Text] [Related]
46. Viral interaction: a possible contributing factor in head and neck cancer progression.
Underbrink MP; Hoskins SL; Pou AM; Albrecht T
Acta Otolaryngol; 2008; 128(12):1361-9. PubMed ID: 18607925
[TBL] [Abstract][Full Text] [Related]
47. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.
Mezhir JJ; Advani SJ; Smith KD; Darga TE; Poon AP; Schmidt H; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2005 Oct; 65(20):9479-84. PubMed ID: 16230412
[TBL] [Abstract][Full Text] [Related]
48. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
Hoffmann D; Wildner O
Cancer Gene Ther; 2007 Jul; 14(7):627-39. PubMed ID: 17479104
[TBL] [Abstract][Full Text] [Related]
49. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
50. An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells.
Fu X; Tao L; Zhang X
Gene Ther; 2007 Aug; 14(16):1218-25. PubMed ID: 17538637
[TBL] [Abstract][Full Text] [Related]
51. Yatein from Chamaecyparis obtusa suppresses herpes simplex virus type 1 replication in HeLa cells by interruption the immediate-early gene expression.
Kuo YC; Kuo YH; Lin YL; Tsai WJ
Antiviral Res; 2006 Jul; 70(3):112-20. PubMed ID: 16540181
[TBL] [Abstract][Full Text] [Related]
52. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy.
Su C; Na M; Chen J; Wang X; Liu Y; Wang W; Zhang Q; Li L; Long J; Liu X; Wu M; Fan X; Qian Q
Mol Cancer Res; 2008 Apr; 6(4):568-75. PubMed ID: 18344493
[TBL] [Abstract][Full Text] [Related]
53. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
[TBL] [Abstract][Full Text] [Related]
54. Induction of sialyl-Lex expression by herpes simplex virus type 1 is dependent on viral immediate early RNA-activated transcription of host fucosyltransferase genes.
Nyström K; Nordén R; Muylaert I; Elias P; Larson G; Olofsson S
Glycobiology; 2009 Aug; 19(8):847-59. PubMed ID: 19369700
[TBL] [Abstract][Full Text] [Related]
55. Oncolytic adenoviral therapy for glioblastoma multiforme.
Sonabend AM; Ulasov IV; Han Y; Lesniak MS
Neurosurg Focus; 2006 Apr; 20(4):E19. PubMed ID: 16709024
[TBL] [Abstract][Full Text] [Related]
56. Alternatively initiated gene 50/RTA transcripts expressed during murine and human gammaherpesvirus reactivation from latency.
Gray KS; Allen RD; Farrell ML; Forrest JC; Speck SH
J Virol; 2009 Jan; 83(1):314-28. PubMed ID: 18971285
[TBL] [Abstract][Full Text] [Related]
57. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
[TBL] [Abstract][Full Text] [Related]
58. Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
[TBL] [Abstract][Full Text] [Related]
59. Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.
Conner J; Braidwood L
Cancer Gene Ther; 2012 Jul; 19(7):499-507. PubMed ID: 22595793
[TBL] [Abstract][Full Text] [Related]
60. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.
Fukuhara H; Takeshima Y; Todo T
Cancer Sci; 2021 Aug; 112(8):3293-3301. PubMed ID: 34036669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
